Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Jeffrey Gundlach and the Lipper Award

TCW Total Return Bond Fund (TGLMX) received a Lipper Award for its five- and ten-year performance. Jeffrey Gundlach was at the helm of the fund for most of this time period, yet someone else receives the award. We are not going to get into the details of Jeff Gundlach‘s nasty battle with TCW, but it is clear that investors should discard the information about TGLMX’s Lipper Award or long-term performance when they decide to invest in the fund. Josh Brown penned a detailed article about this issue:

The problem with this – and the thing that investors need to know – is that these award-winning results were actually generated by Jeffrey Gundlach and his team, about 30 of whom departed TCW in December of 2009. Anyone who had been given trading authority by Gundlach or had worked closely with him, learning his process, has already followed him to his new shop, DoubleLine.

Leaving aside all of the lawsuits and ugliness between TCW and Gundlach upon his departure, if we focus solely on the portfolio management and returns since, we see that the Lipper award and TCW’s attendant PR announcement might be very misleading to investors.

The problem with this – and the thing that investors need to know – is that these award-winning results were actually generated by Jeffrey Gundlach and his team, about 30 of whom departed TCW in December of 2009. Anyone who had been given trading authority by Gundlach or had worked closely with him, learning his process, has already followed him to his new shop, DoubleLine.

Leaving aside all of the lawsuits and ugliness between TCW and Gundlach upon his departure, if we focus solely on the portfolio management and returns since, we see that the Lipper award and TCW’s attendant PR announcement might be very misleading to investors.

Read the rest here.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!